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The origins of this special section on ketamine and ketamine assisted psychotherapy and an overview and deliberately controversial discussion of 
depression and ketamine’s putative efficacy as an anti-
depressant arise from two sources.  The first is a fairly 
widespread and historical appreciation of ketamine’s power 
as a transformative agent, especially when embedded in a 
psychotherapeutic context.  Ketamine is after all the only 
legal psychedelic in use—as a Schedule III substance with 
an indication as a dissociative anesthetic and a long history 
of safe and effective use for anesthesia and analgesia, this 
without significant  respiratory depression.  Other uses 
have occurred, for example in the control of agitated, 
suicidal, and aggressively psychotic individuals in the ER 
setting, and as a transformational, psychedelic experience 
at low to moderate dosages—pre-anesthetic levels—
inspired by the work of Roquet, Jansen, Krupitsky, and 
others.  
More recently, ketamine has come into 
exploration as an anti-depressant, based on an adventitious 
finding of effect in subjects being assessed for the cognitive 
impact of ketamine (see Kolp et al. in this section for a 
more thorough description of this history).  The original 
and early work with ketamine using low to moderate 
transformational medication levels with psychedelic 
impact noted anti-depressant responses related to an 
overall psychological benefit and an “afterglow” that 
could last for up to two weeks time, very similar, and 
seemingly  longer than single dose IV drip administration 
in the current dominant application.  This burgeoning 
of interest in ketamine as an anti-depressant with a 
unique mechanism of action that differentiates it from 
the existing and limitedly efficacious static psychiatric 
arsenal that includes SSRIs, SNRIs, and others is the 
second source of this section.
 Much of the current research focused on 
depression appears to be an attempt to administer 
ketamine intravenously at rates that are slow enough 
and doses that are low enough to avoid much of the 
psychedelic effect that occurs at higher moderate dosages. 
If an experience of psychedelic or dissociative effects 
interferes with an antidepressant  outcome, then such an 
approach would be sensible. On the other hand, if higher 
dosages or the psychedelic experiences that they typically 
produce are both entirely safe and also associated with 
greater antidepressant effect, it is difficult to understand 
the logic of attempting to avoid psychedelic dosages. 
Surely it is time to set aside the old War on Drugs 
narrative, and embrace the use of ketamine for depression 
if there is evidence that it can have significant efficacy 
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in treatment resistant depression and other indications 
without concern for the fact that a psychedelic experience 
may be inseparable from effective therapeutic dosages, 
and may well contribute to the therapeutic effect. In this 
section, Kolp et al. review the numerous new ketamine 
related substances being examined for human use—
substances that are based on the same mechanism of 
action as ketamine but without its psychedelic effects. 
Yet, as Ryan et al. (this issue) note, thus far no new relative 
of ketamine that lacks its dissociative effects has yet to 
show antidepressant efficacy. Still, research is in an early 
stage, and more such work is planned or in process at 
pharmaceutical houses. It remains to be seen whether the 
glutamate/NMDA hypothesis that has emerged around 
the anti-depressant effects of ketamine will be separable 
from its psychedelic effects. 
Can a single chemical have remarkably dissimilar 
effects at different concentrations, or is there a continuum? 
Certainly with regards to dose related anesthetic effect, 
an escalation of effect corresponds to increasing dosage. 
Could there be an anti-depressant effect at very low 
ketamine dosages that disappears as psychedelic effects 
occur?  Not very likely!  If dosage is reduced in an attempt 
to preclude psychedelic effects, at what level is that 
achieved, and how does benefit, such as anti-depressant 
effect, wane or somehow, paradoxically increase?  Where, 
if there is such a thing, does a boundary lie between anti-
depressant effect and interference by psychedelic effect—
this being implied by much of the  research that promotes 
anti-depressant efficacy?  Does investigator bias, the War 
on Drugs, the desire for status and acceptability effect 
research and promulgation?  Whatever the answer to 
that may be, what is presented herein is evidence for 
ketamine’s use to create transformational experiences 
at low to moderate, pre-anesthetic dosages that when 
embedded in a psychotherapeutic approach have great 
potential for emotional healing and the amelioration of 
human suffering and confusion. 
As an introduction to this section, it may be 
useful to consider a broader discussion of depression and 
the implications of phenomena under that heading.
Depression, Anti-Depressants, 
and Transformation
Depression is as old as mammalian life itself.  Grief, the sensations of loss, aloneness, frustrated desire, 
hopelessness, resignation, despair come along with 
mothering—as do attachment, affection, education, 
empathy, protectiveness, and connection.  These are 
inherent to nurturing and raising young to adulthood. 
They are the heart—positive and consequent—of live 
birthing of young—of children—who cannot survive 
on their own.  From this perspective, the negative 
emotional consequences of a particular individual’s 
life are systemic—culturally and situationally 
conditioned within a matrix of local and disparate social 
formations—family, band, tribe, species, interrelated 
and interacting other species in the broad sense of the 
biological community, and its resources—embedded in 
nature and its individual and group potentialities for 
creative engagement.  The vectors and interactions—
the symbioses, dependencies, obligations, potentialities, 
adaptations and threats go in all directions.
Human consciousness has tended towards an 
individual orientation as a distortion—connections 
and connectivities being more unconscious and built 
into the stored complexes that are the substrates of 
our interactive capacities, what in earlier times were 
inadequately termed instincts. We look out from our 
insides and interpret our inputs inside.  This inevitably 
leads to self-absorption and ego formation.  But life, 
our life, is far more complex and interrelated than we 
appreciate—and much of our sensational realm never 
makes it to consciousness, whether it is about our own 
complex multicellular integrations, or our relationships 
externally.  What is exciting about the evolution of 
systemic thought and exploration is that it has opened us 
to the vast web of integrations and effecting influences 
and relationships, and our awareness of this is growing 
exponentially, ever-widening the complexity of our 
understanding, yielding new conceptual schemas that 
are continually being updated, expanded or abandoned.
Psychiatry, as an evolving solidifying guild, now 
too coupled with Big Pharma and compensation through 
the insurance industry, has rubricized and rigidified 
step by step.  Emphasizing consensuality to enable a 
replicable conceptual and compensable schema, it has 
tightened its grip on how mental health practitioners 
think and afflicted the public’s consciousness as 
well.  How often does one use the word “depression” 
mindlessly to compress feelings, or hear, “She’s bipolar,” 
as if that expresses the essence of a person.  We have 
become all too comfortable and accepting of diagnostic 
terminology as if it were real and expressive of our 
realities.  This extends to how depression is measured 
and formalized into a few codes that are supposed to 
cover the vast array of human responses.  
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Such an approach tends to understate the overlap 
between conceptually discrete DSM entities that are really 




lovelessness and many more linkages.  These are all 
embedded in the term depression but not visible, as is so 
much of what occurs to cause depression and is depression 
is not endogenous and not brought on by those who suffer 
with depression. But this is not in the discussion format, 
for in this respect causation is linked directly to culture and 
outside the dominant culture’s acceptable boundaries for 
change—and therefore of psychiatrists’/psychotherapists’ 
responsibilities. Antidepressants may reduce suffering and 
improve functionality to some degree for some people 
and may have an impact on their perspectives as well, but 
going to the “shrink” often has little impact on the chain 
of interlinked contributors to depression. Spuriously 
rigid diagnostic entities do not help the matter, as if, for 
example, PTSD is not a form of depression/agitation, and 
as if most depressions are not trauma or PTSD driven and 
are not linked to anxiety; they are. Psychiatric drugs are 
not all that specific, nor often that helpful, yet they have 
been tied to the development of this constricted view. 
One only has to recall the relationship between certain 
drug companies’ push for the bipolar II category linked 
to the anticonvulsant Lamictal. With the patent expired 
and the availability of the generic lamotrigine—without 
all the hype and the profits, promotion of attention to 
bipolar II has largely gone away.
Adding to this tendency to confine views of 
depression is its measurement as per the indices that 
give the diagnosis—a circularity to be sure—such as the 
Beck Depression Inventory, the Hamilton, the MADRS. 
Those measures used to assess the effect of drugs that 
are in development are constrained by the instruments 
themselves to narrow measures of change.  Yet even 
when administered by blinded researchers, assessment 
is generally obtained by self-report, since subjective 
reporting is truly the only means to obtain information 
on consciousness outside of guesswork by observation, or 
questioning, which are again inevitably self-report based. 
The instruments used tend contain narrowing and often 
confusing questions about how the person feels within 
a very circumscribed framework.  One doesn’t ask, for 
example, how they feel about going back to their difficult 
circumstances; or how they feel about living with that 
person with whom they may be having difficulties; or 
their careers; or being laid off; or about sexuality—the 
latter being especially conspicuous as an omission when 
most of the drugs in use tend to suppress it.  
The following papers on ketamine and its use 
in therapeutic contexts represent a bit of defiance of 
all that conventionality, for its use challenges one to 
understand on a broader level what they are truly about 
as practitioners and human beings.  There are those who 
practice psychiatry/psychotherapy to improve symptoms, 
which may well improve lives.   There are also those 
who practice psychiatry/psychotherapy to change lives. 
Invariably, practitioners do both, or certainly the latter 
group must do both.  At this game, in true modesty, 
mental health practitioners are partly successful at best. 
Our aspiration in producing this section is to assist 
practitioners a bit in improving the practice of helping 
humans to grow, connect, prosper, and reduce their 
suffering.
The Ketamine Papers
I am truly honored to be the guest editor for this Special Topic Section of the International Journal 
of Transpersonal Studies on ketamine—exploring its 
history, uses, pharmacology, therapeutic practice, and its 
potential as a new and novel treatment for depression. 
To call this collection of papers seminal is to understate 
its contribution to the subject. This section assembles 
the core of investigators who have used the substance 
in a variety of therapeutic contexts for over 40 years, 
and whose experience with the transformative and 
therapeutic properties, risks, and clinical successes and 
failures constitutes what is likely the largest body of 
information available on the subject. The reader is invited 
to take time moving through the long and detailed 
contours of this comprehensive undertaking. Later this 
year, these papers will be republished in book form by 
the Multidisciplinary Association for Psychedelic Studies 
(MAPS), together with several additional articles, as The 
Ketamine Papers. 
The section begins with what is to date the most 
thorough review in the literature of the use of ketamine 
for the treatment of depression. Wesley C. Ryan, Cole 
J. Marta, and Ralph J. Koek’s paper, “Ketamine and 
Depression: A Review,” analyzes and segregates studies 
into meaningful categories that enables a thorough 
review of this new field, its claims, and its limitations. 
From this perspective, it is more feasible to evaluate 
that which appears to be plausible, or overstated, 
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or an indication of a vector for further exploration. 
Additionally, the tendency to strip ketamine practice 
of its psychedelic actuality—through adjustment of 
dosage and administration—is also made clear. This 
paper constitutes a pivotal reference point for evaluating 
the view presented in other papers contained in this 
section: that  the transformative nature of ketamine as 
a dissociative agent with psychedelic properties is key 
to its therapeutic potential, including its antidepressant 
efficacy.   
Next in the section is my own study of 
experienced users replicating the “NIMH protocol,” 
as I have called it after the National Institutes of 
Mental Health studies that posited a very low dose 
antidepressant effect. The subjects in my study compared 
the NIMH protocol experience that was duplicated with 
their prior transpersonal experiences of larger IM doses. 
This represents an attempt to understand and feel the 
effects of the low dose as it might pertain to the reported 
experiences that have been called antidepressant. Positing 
a psychological mechanism of action, this paper also 
discusses antidepressant treatment in a novel framework.
The following paper, “Ketamine Psychedelic 
Psychotherapy: Focus on Its Pharmacology, Phenomen-
ology, and Clinical Applications,” by Eli Kolp, Harris 
Friedman, Evgeny Krupitsky, Karl Jansen, Mark Sylvester, 
M. Scott Young, and Ana Kolp, offers a comprehensive 
overview of the development of psychedelic ketamine 
therapy. Eli Kolp’s work with ketamine in a full program 
that he unabashedly entitles Ketamine Psychedelic 
Psychotherapy (KPP) is a thorough approach to working 
with many different diagnoses, addictions, and trauma. 
Kolp’s treatment experience is extensive and his use of 
a variety of supportive and essential techniques, and 
methodologies including MAOIs, diet, meditation, 
and an orientation towards the successful induction of 
transpersonal experiences as healing and transformative 
is unique, daring, and well worth understanding. Evgeny 
Krupitsky began groundbreaking work  with ketamine 
in the former USSR, focusing on alcoholism and 
addiction in inpatient settings using a single and, later, 
two and three administrations of ketamine embedded 
in an intensive abstinence/therapy program. Krupitsky 
has remained in Russia and has had his singular and 
promising work disrupted by a change in the scheduling 
of ketamine to the equivalent of Schedule I claimed to be 
due to a dangerous accelerating street use of the drug. As a 
co-author of this article, Krupitsky brings the perspective 
of his extensive and pioneering experience. Karl Jansen is 
the author of Ketamine: Dreams and Realities, published 
in 2000, which remains the single most thorough and 
intelligent overview of the ketamine experience. Harris 
Friedman is Senior Editor of this journal and a significant 
contributor to the understanding of altered states and 
psychedelic psychotherapy. The remaining authors each 
bring an additional facet of expertise to this compelling 
perspective on ketamine psychotherapy.  
Terrence S. Early offers an in-depth look into 
his practice using ketamine, along with a discussion of 
its history, political issues, and relationships to other 
treatments, in his paper, “Making Ketamine Work in 
the Long Run: The Basics.” Dr. Early’s practice model 
involves primarily the use of intramuscular ketamine—
often with multiple sessions over time—embedded in 
an extensive therapeutic program. His comprehensive 
psychiatry practice, situated on the interface between 
psychiatry, anesthesiology, and psychotherapy, had its 
origins in academia and has continued in an intensive 
clinical practice in the Santa Barbara area that is most 
likely unique in the United States and internationally. 
His work may serve as a guide to the possibilities for using 
this substance, and as a specific reference manual for 
others interested in entering this field of practice. Often 
treating the most damaged and suffering individuals 
with commitment and heart, Early is one of those rare 
lions of medicine who exemplify for all practitioners the 
best efforts to assist and heal those in need.  
Jeffrey Becker practices psychiatry/psycho-
therapy in the Los Angeles and Santa Barbara areas. 
His paper, “Regarding the Transpersonal Nature of 
Ketamine Therapy: An Approach to the Work,” describes 
his use of ketamine as an enfolded part of an overall 
therapeutic method. Combining Edinger’s ego-Self axis 
with aspects of Jungian thought, Becker has created his 
own approach to treating depression with intramuscular 
ketamine and its attendant experiences. He offers an 
explicitly transpersonal perspective for practitioners in 
this clinical field.
A conversation with Richard Yensen brings 
the reader into the realms of Carlos Castaneda, and 
of Salvador Roquet, with whom he had a close and 
enduring relationship. In dialogue with me (Wolfson), 
Yensen shares rich accounts from the history of 
ketamine therapy in the piece, “Psychedelic Experiential 
Pharmacology: Pioneering Clinical Explorations with 
Salvador Roquet.” Roquet left his mark on psychedelic 
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psychotherapy in which ketamine came to play a 
significant part as an egolytic and then reconstitutive 
agent along with other psychedelics. It was Roquet who 
principally introduced ketamine practice into the small 
world of psychedelic practitioners, of which Richard 
Yensen was a part along with such luminaries as Stanislav 
Grof and Stanley Krippner. Yensen provides the details 
of Roquet’s art form, which to this day influences many 
practitioners. The psychedelic world has always had a 
bell shape to it: There are the heroic take-it-as-far-as-
you-can-go dissolusionists, or psychotomimeticists bent 
on crushing ego and then reassembling; and the step-by 
step cautionists who build the experience and practice 
a more classical psychotherapy approach. In between, 
there are those of all stripes. Over time and with 
experience, practitioners will shift positions and modify 
their practices. A second continuum that may occur to 
readers is the “hard-head to vulnerable” spectrum—on 
the one hand a sense of anxiety about going too far, and 
on the other a sense of loss from not going far enough. 
There are two aspects: Each person is built differently 
with different tolerances and physical vulnerabilities. 
Each tends to either exaggerate or understate these. 
Most have a fear of losing their minds; of their minds 
betraying them; of madness lurking if they do too much 
of something or other; of a distrust of their core sanity. 
These too change with time and experience, albeit we 
humans are often best served by recognizing our limits 
and limitations. Yensen offers an intimate view of Roquet 
as a man who pushed limits, and seemed without fear of 
going too far.
On a more personal and anecdotal level, the 
next paper is a collection that offers three first-person 
reports entitled, “Ethnographic Accounts of Ketamine 
Explorations in Psychedelic Culture,” by Kenneth Ring, 
Ralph Metzner, and Philip E. Wolfson. Ken Ring, one 
of the great progenitors of research on the near death 
experience (NDE), regales with an account of his 
first powerful ketamine experiences in a way that also 
recollects the culture of Esalen Institute in the 1980s. 
In fact, there was a significant underground use of 
ketamine that paralleled on a smaller scale the then legal 
exploration of MDMA for psychotherapy and peaceful 
transformation of interpersonal relationships. Ken’s 
personal account serves as an in-depth exemplar of the 
feel of a first time experience—though certainly not 
the only feel, as the breadth of ketamine experience is 
not subject to compartmentalization. This was also the 
era when John Lilly made his appearance in the Esalen 
circles, and Ralph Metzner shares a brief account of 
Lilly as he both exhilarated us with the possibilities of 
ketamine’s psychedelic properties for transformation 
and transpersonal experiences, and horrified us at its 
addictive potential. Viewing ketamine’s potential for 
dependency through John Lilly, I provide brief closing 
remarks as a warning of the possibility of the poison 
path arising from ketamine use. Ketamine’s putative 
mechanism of action(s) does not reside in the usual self-
reward dopaminergic path; instead, its allure may well 
be of a different nature, a possibility that is discussed.
Included in the section is, “Ketamine (IM) 
Assisted Psychotherapy (KAP): A Model for Informed 
Consent,” which potentially may serve others as they 
consider including ketamine in their own clinical work. 
This sample informed consent form is intentionally 
comprehensive and lengthy. Though it builds on the 
prior work of Eli Kolp and Terry Early, this consent 
form reflects my own engagement with the challenges 
of effectively providing informed consent for KAP and 
is my responsibility.
The final piece in the Section presents my own 
schema for conceptualizing transformation—a topic 
of some relevance since a major claim of this Section 
is that Ketamine Assisted Psychotherapy’s value is 
inextricably linked with the psychedelic experiences that 
ketamine induces—experiences that are often reported 
as psychologically transformative processes. My hope 
is that this piece will serve as a fulcrum for discussion, 
amplification, and healthy controversy. .  Included in 
the paper is a taxonomy offered as a meta-structure 
for examining transformation with psychedelics, 
the formats presented being derived principally 
from ketamine experiences, but also having wider 
applicability. A ‘transformation codex’ is included as a 
matrix for characterizing one’s own personal histories of 
transformational experiences.
As you read these papers, here are some points 
to consider:
• The complexity of our evolved brain/mind/
consciousness/connectivity makes reductionist and 
narrow concepts and explanations for complex and 
varied states of mind like depression unhelpful, off 
the mark and superficial.  DSM diagnoses are circular 
and tautological defining depression as a cluster of 
the symptoms that in turn define depression.  They 
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take the complexity of human beings out of the 
analysis and create deep mystification in all of us as 
we think about ourselves and others.
•    The concept of antidepressants is at its core complex 
and varied and the restriction in thinking primarily 
about drug interventions serves the pharmaceutical 
industry and the officials who are in charge of the 
self-interested fabrication of depression as disease. 
•    Within the realm of psychiatric medicine there are 
many types of drugs said to be antidepressants and 
the fact that 20% to 50% of people do not respond 
to drugs based on the neurotransmitter model of 
depression strongly suggests that this approach 
has serious flaws. The chemical imbalance that 
is theorized as the source of depression is elusive, 
and though it sounds empirical, there is no actual 
evidence that such an imbalance exists in actual 
individuals. 
•       A very partial list of antidepressants includes multiple 
types of chemical antidepressants with very different 
neurotransmitter actions and myriad other means 
to obtain antidepressant effects: anticonvulsants, 
stimulants, marijuana, exercise, meditation, 
hedonism, temporary satisfaction of cravings, 
elimination of cravings, oxytocin, sexuality, spiritual 
practice, money, love, children, activism, justice, a 
good job, respect, friendship, education, a good 
book, a bad book, and so on.
•   Most depressive episodes come to an end without 
psychiatrists and without therapy. Some depressions 
begin with psychiatrists and psychotherapists.
•    There appears to be a continuum between anxiety, 
trauma, and depression, and most often they are 
mingled.
•     There are so many aspects of being and being in 
the world, and they all reflect and infect mood. 
All evaluations are oversimplifications. Even a 







education-origins and history of oppression-
parenting-grief and loss-responsibilities-family-
addictions, and so on.
Humans are complex, and “character,” though 
it is tempting to see it as evanescent, not essential, and 
malleable, has its rigidity and implacability in all of 
us. After all, being a “shrink” is really a scholarship to 
watch oneself, as well as others. The argument here is 
that transformative work generally trumps symptom 
relief—and contains the latter within its effect size. In 
other words, in my humble view, ketamine really is not 
very promising as a low-dose anti-depressant. Low dose 
ketamine treatment does not do much, and it does not do 
it for very long. Embedded in a repetitive psychotherapy 
format, its success rate for depression increases. In most 
studies, it appears impossible to reliably strip ketamine 
of some element of mild dissociative experience, as if 
they were merely some undesirable “side effect.” Even 
at a low dose, its effect is felt as being mildly “stoned.” 
If even that minimal change of consciousness does not 
occur or Is deliberately stripped from administration 
of ketamine, I believe there is then no therapy and no 
possibility of even a modest anti-depressant effect. After 
all, this is not homeopathy! 
This section sets out the history, the practice, the 
pharmacology, the effects, various therapeutic contexts, 
and the literature on ketamine as a psychedelic and as an 
antidepressant. I hope you enjoy the controversy.  You be 
the judge
Philip E. Wolfson
Center for Transformational Psychotherapy
San Francisco and San Anselmo, CA
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